Companies at EFIB set to drive the bioecon...Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately. more ➔
Oxford Nanopore wins over AmgenOxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company. more ➔
French Acticor Biotech raises €15.3mIn a Series B financing round, INSERM spin-off Acticor Biotech has raised €15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical … more ➔
HiFiBiO bags immuno-oncology specialist H-...Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, … more ➔
Phase III success for Roche breast cancer...Roche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients. more ➔
Targovax reports promising disease-free su...Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer. more ➔
EU set to speed up switch to bioeconomy by...Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased … more ➔
Bacterial antigen mimicry drives MST cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS). more ➔
Affimed halts trial after patient death an...Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I … more ➔
Sitryx Therapeutics bags $30m in Series A...Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and … more ➔
